Aditxt, Inc. Files 8-K with Financials and Exhibits

Ticker: ADTX · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1726711

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

Aditxt filed an 8-K on 12/11/24 with financials and exhibits.

AI Summary

On December 11, 2024, Aditxt, Inc. filed an 8-K report to disclose information under Regulation FD. The filing also includes financial statements and exhibits. The company, formerly known as Aditx Therapeutics, Inc., is incorporated in Delaware and its principal executive offices are located in Mountain View, California.

Why It Matters

This 8-K filing provides an update on Aditxt, Inc.'s corporate activities and financial reporting, which is crucial for investors to assess the company's current status and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Aditxt, Inc.?

The primary purpose of this 8-K filing is to report information under Regulation FD Disclosure and to include Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on December 11, 2024.

What were Aditxt, Inc.'s former company names?

Aditxt, Inc. was formerly known as Aditx Therapeutics, Inc. and ADiTx Therapeutics, Inc.

In which state is Aditxt, Inc. incorporated?

Aditxt, Inc. is incorporated in Delaware.

Where are Aditxt, Inc.'s principal executive offices located?

Aditxt, Inc.'s principal executive offices are located at 2569 Wyandotte Street, Suite 101, Mountain View, CA 94043.

Filing Stats: 600 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-12-12 16:15:14

Key Financial Figures

Filing Documents

01 Regulation

Item 7.01 Regulation FD Disclosure On December 12, 2024, Aditxt, Inc. (the " Company ") issued a press release announcing that its subsidiary, Adimune, Inc. (" Adimune ") has successfully completed preclinical efficacy and safety studies for its immune modulation therapeutic platform. A copy of the press release is furnished to this Current Report on Form 8-K as Exhibit 99.1 The Company has prepared presentation materials (the " Presentation ") regarding Adimune. The Presentation was posted to Adimune's website on December 11, 2024 and is furnished to this Current Report on Form 8-K as Exhibit 99.2 The information in this Item 7.01 and Exhibit 99.1 and 99.2 of this Current Report on Form 8-K is furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in any such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Exhibit 99.1 Press release dated December 12, 2024 99.2 Adimune Presentation 104 Cover Page Interactive Data File (embedded within the XBRL document) -1- SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 12, 2024 Aditxt, Inc. By: /s/ Amro Albanna Name: Amro Albanna Title: Chief Executive Officer -2-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing